We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2600:HKEXAluminum Corporation of China Limited Class H Analysis

Data as of 2026-05-17 - not real-time

HK$10.54

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Aluminum Corporation of China Limited (CHALCO) is trading at HK$10.54, well below its 20‑day SMA of 11.68 and the 50‑day SMA of 12.16, indicating short‑term weakness. However, the price sits just above the identified support at HK$10.46 and the 200‑day SMA of 10.51, providing a technical floor. The RSI of 36 suggests the stock is not yet oversold, while a bearish MACD histogram reinforces near‑term downside pressure. Despite this, the company’s fundamentals are robust: a forward PE of 7×, a trailing PE of 10.6×, and a DCF‑derived fair value of about HK$19.5 imply ~44% upside. Strong cash generation (operating cash flow HK$38.7bn) and a healthy ROE of 21% support the valuation case.
The dividend yield of 2.86% with a modest 30% payout ratio appears sustainable given ample free cash flow and a net‑debt position of roughly HK$22bn. Volatility is elevated at 51% over 30 days, but beta is sub‑1 (≈0.79), tempering market‑wide swings. Sector exposure to cyclical aluminium demand and Chinese regulatory environment adds medium‑level risk, while liquidity is solid thanks to high trading volumes. Overall, the stock presents a compelling blend of value and growth attributes, making it attractive across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price near technical support with upside potential
  • Strong cash flow supporting dividend
  • Undervaluation relative to DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Projected earnings growth and low forward PE
  • Sustained dividend yield
  • Improving aluminium market fundamentals

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term demand for aluminium and strategic assets
  • Robust ROE and solid balance sheet despite leverage
  • Significant upside to intrinsic value

Key Metrics & Analysis

Financial Health

Revenue Growth4.80%
Profit Margin6.01%
P/E Ratio10.6
ROE20.88%
ROA9.77%
Debt/Equity44.36
P/B Ratio1.9
Op. Cash FlowHK$38.7B
Free Cash FlowHK$22.0B

Technical Analysis

TrendNeutral
RSI36.1
SupportHK$10.46
ResistanceHK$13.27
MA 20HK$11.68
MA 50HK$12.16
MA 200HK$10.51
MACDBearish
VolumeIncreasing
Fear & Greed Index88.52

Valuation

Fair ValueHK$19.49
Target PriceHK$15.24
Upside/Downside44.63%
GradeUndervalued
TypeBlend
Dividend Yield2.86%

Risk Assessment

Beta0.79
Volatility50.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.